• An early-stage Moderna or BioNTech, but focusing on DNA-based immunotherapies for cancer.
• Like a smaller, developing version of a company such as Genentech or Bristol Myers Squibb, specifically targeting cancers with DNA-based therapies.

• GEN-1: A DNA-based immunotherapy designed for the localized treatment of ovarian cancer.
• ThermoDox: A proprietary heat-activated liposomal encapsulation of doxorubicin, currently in development for various cancer indications.
• Platform Technologies: Two feasibility stage platforms for developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.

As a clinical stage biotechnology company, Imunon (IMNN), formerly Celsion Corporation, is primarily focused on the research, development, and clinical trials of its product pipeline (GEN-1 and ThermoDox). At this stage, the company does not have major commercial customers in the traditional sense, as its products are still under development and not yet approved for sale or commercial distribution.

Major Suppliers for Imunon (IMNN):

• Lonza Group AG (Symbol: LONN.SW)
• Ajinomoto Co., Inc. (Symbol: TYO: 2802)

Stacy R. Lindborg, PhD, President, Chief Executive Officer, and Board Director

Dr. Lindborg was appointed President and CEO of Imunon, Inc. effective May 13, 2024. She brings nearly 30 years of pharmaceutical and biotech industry experience, with expertise in R&D, regulatory affairs, executive management, and strategy development. Prior to joining Imunon, she served as Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics, where she continues to be a member of the board of directors. She previously held the position of Vice President & Global Analytics and Data Sciences Head at Biogen and spent 16 years at Eli Lilly and Company, where her roles included Head of R&D strategy.

Kimberly Graper, Interim Chief Financial Officer

Ms. Graper was appointed Interim Chief Financial Officer of Imunon, Inc. effective June 13, 2025. She joined the company in October 2022 as Vice President of Finance and Corporate Controller. Before Imunon, she gained experience at various companies including F2G Inc., Timber Pharmaceuticals, Inc., Anticimex Inc., and Derma Sciences. She also held senior financial positions at Hunterdon Healthcare System and started her career in public accounting at Amper, Politziner & Mattia. Ms. Graper is a Certified Public Accountant in New Jersey and holds a Bachelor of Science in Accounting from Clemson University and a Juris Doctor from Seton Hall School of Law.

Douglas V. Faller, MD, PhD, Chief Medical Officer

Dr. Faller was appointed Chief Medical Officer of Imunon, Inc. effective February 18, 2025. He has over 30 years of experience in the industry, academia, and laboratory settings, with a specialization in oncology and immunology. His previous roles include serving as Chief Medical Officer at Skyhawk Therapeutics and Oryzon Genomics, and holding executive positions at Takeda.

Kristin Longobardi, MBA, Senior Vice President, Strategic Operations

Susan Eylward, General Counsel & Corporate Secretary

Key Risks to Imunon (IMNN)

1. Clinical Trial Outcomes and Regulatory Approval

   As a clinical-stage biotechnology company, Imunon's success is heavily contingent on the successful completion and positive outcomes of its clinical trials, particularly the pivotal Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer. Clinical trials are inherently expensive, time-consuming, and carry a significant risk of failure; interim results do not guarantee final success. Furthermore, while IMNN-001 aims to mitigate historical challenges associated with IL-12 therapies, such as hepatic toxicity and cytokine release syndrome, there remains a risk that the therapy may not achieve the desired efficacy or safety profile in late-stage trials. Even with successful trial data, there is no guarantee of regulatory approval from health authorities, which is essential for commercialization.

2. Financial Viability and Funding

   Imunon faces significant financial challenges, evidenced by substantial accumulated losses and current liabilities exceeding current assets, which raise considerable doubt about the company's ability to continue as a going concern. The company has a tight cash position and a significant accumulated deficit, which could impact its liquidity and operational sustainability. The ability to secure additional capital and favorable funding terms, especially amidst broader economic pressures, is critical for funding ongoing research and development activities and advancing its product pipeline.

3. Competition and Market Acceptance

   Despite addressing a significant unmet need in advanced ovarian cancer, Imunon operates in a highly competitive pharmaceutical and biotechnology market. While the standard of care for this disease has seen limited advancements in decades, and other immunotherapies like checkpoint inhibitors have shown inconsistent benefits, new treatments from competitors could emerge. Even if IMNN-001 receives regulatory approval, its commercial success will depend on its ability to demonstrate a compelling value proposition, gain market acceptance, and compete effectively with existing and future therapies.

Imunon (symbol: IMNN) has two main products in development, GEN-1 and ThermoDox, targeting different cancer markets.

For GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer, the global ovarian cancer drugs market was valued at approximately USD 4.09 billion in 2025 and is projected to reach around USD 7.78 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.64% during this period. North America is a dominant region in the ovarian cancer market, holding over 40% of the global market share in 2023. The U.S. ovarian cancer drugs market size alone is estimated at USD 1.30 billion in 2025 and is projected to reach approximately USD 2.57 billion by 2035.

For ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin for various cancer indications, the global doxorubicin market size was valued at approximately USD 1.33 billion in 2024. This market is projected to reach USD 2.13 billion by 2033, with a CAGR of 5.06% from 2025 to 2033. Doxorubicin is used in the treatment of a range of cancers, including breast, lung, ovarian, and bladder cancer, as well as hematological malignancies like leukemia and lymphoma.

For Imunon (NASDAQ: IMNN), the expected drivers of future revenue growth over the next 2-3 years are primarily tied to the advancement and commercialization of its lead immunotherapy candidate, IMNN-001, and strategic leveraging of its underlying technology platforms:

1. Successful Completion and Regulatory Approval of the Phase 3 OVATION 3 Study for IMNN-001 in Advanced Ovarian Cancer: Imunon's most significant near-term revenue driver hinges on the successful completion of its pivotal Phase 3 OVATION 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer. The company initiated this 500-patient trial in Q1 2025, with enrollment advancing ahead of internal targets. Positive interim analyses and subsequent Biologics License Application (BLA) filing, especially for the homologous recombination deficiency positive (HRD+) population, are crucial steps towards potential market approval and thus, revenue generation. The FDA has aligned with Imunon on the Phase 3 trial protocol and manufacturing strategy, which supports the drug's path toward commercialization. IMNN-001 has received Fast Track and Orphan Drug designations, which could expedite its regulatory pathway.
2. Commercial Launch and Market Penetration of IMNN-001 for Advanced Ovarian Cancer: Following regulatory approval, the primary driver of revenue will be the commercial launch and subsequent market penetration of IMNN-001. Analysts project that Imunon will begin generating revenue in 2028. IMNN-001 has demonstrated compelling results in Phase 2 studies, including a median 13-month increase in overall survival for patients with newly diagnosed advanced ovarian cancer. The significant unmet medical need in this patient population, with approximately 20,000 new cases annually in the U.S. and high recurrence rates, indicates a substantial market opportunity. Imunon's cGMP-compliant in-house manufacturing capabilities may contribute to high gross margins upon potential FDA approval.
3. Strategic Partnerships and Licensing Agreements for IMNN-001 or the TheraPlas Platform: Imunon is actively pursuing business development initiatives, which are identified as key milestones for 2026 and beyond. The TheraPlas platform, the underlying technology for IMNN-001, has broader potential for delivering various therapeutic payloads. Opportunities for growth through partnerships, including potential licensing deals in regions like Asia-Pacific, could provide non-dilutive funding, expanded market reach, and upfront payments or royalty streams, thereby contributing to future revenue.
4. Expansion of IMNN-001's Label or Development into Additional Oncology Indications: While initially focused on advanced ovarian cancer, the long-term potential for IMNN-001's revenue growth could come from expanding its approved label to include other ovarian cancer patient subgroups or from developing the therapy for other solid tumor indications. The company has completed animal experiments with IMNN-001 in additional tumor types, suggesting a broader applicability for the TheraPlas platform beyond its current lead indication. Such expansions would increase the addressable market and sustained revenue streams.